Liang Juanying, Nong Shaoyun, Jiang Liejun, Chi Xiaowei, Bi Dewu, Cao Jun, Mo Lida, Luo Xiaolu, Huang Huayi
Department of Laboratory Medicine, The Forth People's Hospital of Nanning City, Nanning, China.
Department of Laboratory Medicine, Guangxi Nationalities Hospital, Nanning, China.
J Clin Lab Anal. 2021 Jan;35(1):e23609. doi: 10.1002/jcla.23609. Epub 2020 Nov 21.
For better understanding of the pathological changes of COVID-19, benefiting clinical management of the disease and the preparation for future waves of similar pandemics.
Hematology parameters from a total of 52 cases of COVID-19 admitted for treatment in a designated hospital were retrospectively analyzed. Data were analyzed by SPSS statistical software.
Pre-treatment T-cell subsets, total lymphocytes, red blood cell distribution width (RDW), eosinophils, and basophils were significantly lower than that of post-treatment, while the inflammatory indexes neutrophils, neutrophil to lymphocyte ratio (NLR), and C-reactive protein (CRP) levels, as well as red blood cell (RBC) and hemoglobin, were significantly reduced after treatment. The T-cell subsets, total lymphocytes, and basophils in severely and critically ill patients were significantly lower than those in moderately ill patients. Neutrophils, NLR, eosinophils, procalcitonin (PCT), and CRP was significantly higher in severely and critically ill patients than in moderately ill patients. CD3+, CD8+, total lymphocytes, platelets, and basophils in patients older than 50 were lower than that of those younger than 50, while neutrophils, NLR, CRP, and RDW in patients older than 50 were higher than that of younger than 50. There was a positive correlation among prothrombin time (PT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in severely and critically ill patients.
T-cell subsets, lymphocyte count, RDW, neutrophils, eosinophils, NLR, CRP, PT, ALT, and AST are important indicators in the management especially for severely and critically ill patients with COVID-19.
为了更好地了解新型冠状病毒肺炎(COVID-19)的病理变化,以利于该疾病的临床管理以及为未来类似大流行的应对做准备。
回顾性分析了在一家定点医院接受治疗的52例COVID-19患者的血液学参数。数据采用SPSS统计软件进行分析。
治疗前T细胞亚群、淋巴细胞总数、红细胞分布宽度(RDW)、嗜酸性粒细胞和嗜碱性粒细胞显著低于治疗后,而炎症指标中性粒细胞、中性粒细胞与淋巴细胞比值(NLR)和C反应蛋白(CRP)水平,以及红细胞(RBC)和血红蛋白在治疗后显著降低。重症和危重症患者的T细胞亚群、淋巴细胞总数和嗜碱性粒细胞显著低于中症患者。重症和危重症患者的中性粒细胞、NLR、嗜酸性粒细胞、降钙素原(PCT)和CRP显著高于中症患者。50岁以上患者的CD3+、CD8+、淋巴细胞总数、血小板和嗜碱性粒细胞低于50岁以下患者,而50岁以上患者的中性粒细胞、NLR、CRP和RDW高于50岁以下患者。重症和危重症患者的凝血酶原时间(PT)、丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)之间存在正相关。
T细胞亚群、淋巴细胞计数、RDW、中性粒细胞、嗜酸性粒细胞、NLR、CRP、PT、ALT和AST是COVID-19管理中的重要指标,尤其是对重症和危重症患者。